Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Silence Therapeutics Plc - American Depository Share (NQ:SLN)

6.340 +0.060 (+0.96%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jul 25, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Silence Therapeutics Plc - American Depository Share

< Previous 1 2 3 4 5 Next >
Is This A Miracle Drug For 'Sticky Cholesterol'? Analysts Applaud Safety, Efficacy Of Silence Therapeutics' Heart Disease Candidate
Earlier today, Silence Therapeutics plc (NASDAQ: SLN) announced topline results from the multiple-dose component of the APOLLO phase 1 study of zerlasiran (formerly SLN360) in 36 adults with baseline... 
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session
 
Via Benzinga
Silence Therapeutics Announces Positive Topline Results from Phase 1 Multiple Dose Study of Zerlasiran in Subjects with High Lipoprotein(a) and Stable Atherosclerotic Cardiovascular Disease
From Silence Therapeutics plc
Via Business Wire
Silence Therapeutics to Participate in Fireside Chat at Chardan’s 7th Annual Genetic Medicines Conference
From Silence Therapeutics plc
Via Business Wire
Where Silence Therapeutics Stands With Analysts
 
Via Benzinga
What 6 Analyst Ratings Have To Say About Silence Therapeutics
 
Via Benzinga
Silence Therapeutics to Participate in September Investor Conferences
From Silence Therapeutics plc
Via Business Wire
Silence Therapeutics Reports Second Quarter 2023 Results
From Silence Therapeutics plc
Via Business Wire
Silence Therapeutics Achieves $4 Million in Research Milestone Payments from Hansoh Pharma Collaboration
From Silence Therapeutics plc
Via Business Wire
The Latest Analyst Ratings for Silence Therapeutics
 
Via Benzinga
Earnings Scheduled For August 10, 2023
Companies Reporting Before The Bell • IDEX Biometrics (NASDAQ:IDBA) is estimated to report quarterly loss at $0.39 per share on revenue of $1.60 million. 
Via Benzinga
Silence Therapeutics to Present at the Jefferies Healthcare Conference
From Silence Therapeutics plc
Via Business Wire
Silence Therapeutics Reports First Quarter 2023 Results
From Silence Therapeutics plc
Via Business Wire
Benzinga's Top Ratings Upgrades, Downgrades For May 8, 2023
 
Via Benzinga
Silence Therapeutics Achieves $10 Million Milestone Payment from AstraZeneca Collaboration
From Silence Therapeutics plc
Via Business Wire
Silence Therapeutics Completes Enrollment in Phase 2 Study of Zerlasiran (SLN360) in Subjects with Elevated Lipoprotein(a) at High Risk of Atherosclerotic Cardiovascular Disease Events
From Silence Therapeutics plc
Via Business Wire
Silence Therapeutics to Participate in Fireside Chat at H.C. Wainwright BioConnect Investor Conference
From Silence Therapeutics plc
Via Business Wire
Stocks That Hit 52-Week Lows On Tuesday
  Tuesday's session saw 286 companies set new 52-week lows. 
Via Benzinga
Stocks That Hit 52-Week Lows On Monday
  On Monday, 147 stocks made new 52-week lows. 
Via Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
 
Via Benzinga
Silence Therapeutics Announces Publication in Blood Demonstrating Role for Iron Regulation in Polycythemia Vera
From Silence Therapeutics plc
Via Business Wire
Stocks That Hit 52-Week Lows On Friday
  During Friday's session, 149 stocks hit new 52-week lows. 
Via Benzinga
Stocks That Hit 52-Week Lows On Wednesday
  On Wednesday, 81 companies hit new 52-week lows. 
Via Benzinga
Silence Therapeutics to Present at Guggenheim’s Genomic Medicines and Rare Disease Days
From Silence Therapeutics plc
Via Business Wire
Silence Therapeutics Appoints Dr. Steven Romano as Incoming Chief Medical Officer and Head of Research and Development
From Silence Therapeutics plc
Via Business Wire
Silence Therapeutics to Buyback siRNA Complement Assets
From Silence Therapeutics plc
Via Business Wire
Earnings Scheduled For March 15, 2023
Companies Reporting Before The Bell • Sportradar Gr (NASDAQ:SRAD) is estimated to report quarterly earnings at $0.04 per share on revenue of $208.09 million. 
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
 
Via Benzinga
Silence Therapeutics Reports Fourth Quarter and Full Year 2022 Results
From Silence Therapeutics plc
Via Business Wire
Silence Therapeutics to Report Fourth Quarter and Full Year 2022 Results on March 15, 2023
From Silence Therapeutics plc
Via Business Wire
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.